208 related articles for article (PubMed ID: 21216303)
1. Family friction as ΔNp73 antagonises p73 and p53.
Bailey SG; Cragg MS; Townsend PA
Int J Biochem Cell Biol; 2011 Apr; 43(4):482-6. PubMed ID: 21216303
[TBL] [Abstract][Full Text] [Related]
2. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
[TBL] [Abstract][Full Text] [Related]
3. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
[TBL] [Abstract][Full Text] [Related]
4. Targeting p73--a potential approach in cancer treatment.
Slade N; Horvat A
Curr Pharm Des; 2011; 17(6):591-602. PubMed ID: 21391909
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
Vilgelm A; El-Rifai W; Zaika A
Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
[TBL] [Abstract][Full Text] [Related]
6. Relative expression of TAp73 and ΔNp73 isoforms.
Conforti F; Yang AL; Agostini M; Rufini A; Tucci P; Nicklison-Chirou MV; Grespi F; Velletri T; Knight RA; Melino G; Sayan BS
Aging (Albany NY); 2012 Mar; 4(3):202-5. PubMed ID: 22388545
[TBL] [Abstract][Full Text] [Related]
7. TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.
Hassan HM; Dave BJ; Singh RK
Curr Mol Med; 2014 May; 14(4):432-9. PubMed ID: 24730526
[TBL] [Abstract][Full Text] [Related]
8. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells.
Nakagawa T; Takahashi M; Ozaki T; Watanabe K; Hayashi S; Hosoda M; Todo S; Nakagawara A
Cancer Lett; 2003 Jul; 197(1-2):105-9. PubMed ID: 12880968
[TBL] [Abstract][Full Text] [Related]
9. Tissue-specific expression of p73 C-terminal isoforms in mice.
Grespi F; Amelio I; Tucci P; Annicchiarico-Petruzzelli M; Melino G
Cell Cycle; 2012 Dec; 11(23):4474-83. PubMed ID: 23159862
[TBL] [Abstract][Full Text] [Related]
10. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
Muttray AF; Cox RL; Reinisch CL; Baldwin SA
Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
[TBL] [Abstract][Full Text] [Related]
11. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
12. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.
Petrenko O; Zaika A; Moll UM
Mol Cell Biol; 2003 Aug; 23(16):5540-55. PubMed ID: 12897129
[TBL] [Abstract][Full Text] [Related]
13. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
14. Regulation of p73 activity by post-translational modifications.
Conforti F; Sayan AE; Sreekumar R; Sayan BS
Cell Death Dis; 2012 Mar; 3(3):e285. PubMed ID: 22419114
[TBL] [Abstract][Full Text] [Related]
15. Oncoprotein E7 from beta human papillomavirus 38 induces formation of an inhibitory complex for a subset of p53-regulated promoters.
Saidj D; Cros MP; Hernandez-Vargas H; Guarino F; Sylla BS; Tommasino M; Accardi R
J Virol; 2013 Nov; 87(22):12139-50. PubMed ID: 24006445
[TBL] [Abstract][Full Text] [Related]
16. Functions, divergence and clinical value of TAp73 isoforms in cancer.
Logotheti S; Pavlopoulou A; Galtsidis S; Vojtesek B; Zoumpourlis V
Cancer Metastasis Rev; 2013 Dec; 32(3-4):511-34. PubMed ID: 23592418
[TBL] [Abstract][Full Text] [Related]
17. p63 and p73: roles in development and tumor formation.
Moll UM; Slade N
Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
[TBL] [Abstract][Full Text] [Related]
18. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
Zhang L; Nie L; Maki CG
Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
[TBL] [Abstract][Full Text] [Related]
19. Structure and apoptotic function of p73.
Yoon MK; Ha JH; Lee MS; Chi SW
BMB Rep; 2015 Feb; 48(2):81-90. PubMed ID: 25441426
[TBL] [Abstract][Full Text] [Related]
20. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
